GlassScriptPhysician profile
Srinivas Mendu
NPI 1245235126
$9,104.75
in general payments reported to CMS, 2019-2025
37 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $1,104 · 2021: $1,469 · 2022: $1,395 · 2023: $1,120 · 2024: $1,088 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,437.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,658.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.13 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $985.33 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $919.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $430.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $346.73 | 2019-2025 | Capvaxive |
| Glaxosmithkline, LLC. | $311.72 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $253.77 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $195.90 | 2019-2023 | |
| Exact Sciences Corporation | $184.56 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $179.58 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.97 | 2020-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $143.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $129.88 | 2019-2021 | |
| Dexcom, INC. | $120.53 | 2021-2025 | Dexcom G6 Transmitter |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $86.89 | 2022-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $80.78 | 2019-2021 | |
| Allergan, INC. | $74.03 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $70.81 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $68.85 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $67.69 | 2021 | |
| Phadia US INC. | $60.05 | 2019-2021 | |
| Daiichi Sankyo INC. | $58.65 | 2022-2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $46.68 | 2022 | |
| Redhill Biopharma INC. | $41.43 | 2020-2022 | |
| Esperion Therapeutics, INC. | $41.02 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $37.35 | 2021-2022 | |
| Boston Scientific Corporation | $35.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.63 | 2024-2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $28.07 | 2022 | |
| Genentech USA, INC. | $26.98 | 2019-2020 | |
| Corcept Therapeutics | $19.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.95 | 2023 | Eliquis |
| Scynexis, INC. | $15.27 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $13.99 | 2019 | |
| Seqirus USA INC | $13.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Mendu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.